Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation.
Wang
Hengxiang
H
Zhu
Ling
L
Xue
Mei
M
Liu
Jing
J
Guo
Zikuan
Z
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000097:blood / Q000517:prevention & control*; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D010750:Phosphoproteins / Q000097:blood; D014184:Transplantation, Homologous; D014763:Viral Matrix Proteins / Q000097:blood; D014766:Viremia / Q000097:blood / Q000517:prevention & control*
D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C464963:pp67 protein, human cytomegalovirus; D017245:Foscarnet